U.S. Mulls Registration Fees For Foreign Drug Manufacturers
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA could raise another $5.1 million from foreign inspections of drug manufacturing facilities, Sen. Grassley says.
You may also be interested in...
FDA’s Poor Performance “Invites Catastrophe,” House Investigator Says
Good public health response, poor regulatory oversight mark adulterated heparin episode, Nelson testifies.
FDA’s Poor Performance “Invites Catastrophe,” House Investigator Says
Good public health response, poor regulatory oversight mark adulterated heparin episode, Nelson testifies.
Baxter Heparin Case Highlights Global Supply Chain Vulnerabilities
Correct paperwork no guarantee even legitimate API manufacturers operate according to Chinese govt. standards, chemical exec says.